NIKKEI 225
29,161.80+213.07(+0.74%)HANG SENG
28,842.13+103.23(+0.36%)CRUDE OIL
70.910.00(0.00%)
IQVIA Holdings Inc. (0JDM.L)
| Previous close | 236.94 |
| Open | 245.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 245.00 - 245.00 |
| 52-week range | 245.00 - 245.00 |
| Volume | 2 |
| Avg. volume | N/A |
| Market cap | 48.835B |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | 116.67 |
| EPS (TTM) | 2.10 |
| Earnings date | 20 Jul 2021 - 26 Jul 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Q² Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK
MORRISVILLE, N.C., Jun 14, 2021--Q2 Solutions, a leading global clinical trial laboratory services organization and a wholly owned subsidiary of IQVIA, has announced the expansion of its laboratory and operational capabilities at its Alba Campus in Livingston, Scotland. This expansion of central labs, genomics, flow cytometry, and translational science laboratory services will support new growth areas for biopharma and pharma clients around the world and drive better patient outcomes.
- Zacks
IQVIA Holdings (IQV) Stock Up 55.4% Over a Year: Here's Why
IQVIA Holdings (IQV) stock is riding on consecutive better-than-expected top- and bottom-line performances, and an encouraging yearly guidance.
- Business Wire
Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials
Q2 Solutions, a wholly-owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, today announced a transformative collaboration with Tasso Inc., a pioneer in clinical-grade, at-home, patient-centered blood testing, to develop diagnostic tests used in decentralized (virtual) clinical trials. These new laboratory-developed tests will use Tasso’s devices, enabling patients to collect their own blood using a virtually painless process from anywhere at any time.
